The transcription factor C/EBP? is required for regulation of the balance between differentiation and proliferation during the early stages of myelopoiesis. The importance of this function is demonstrated by the observation that C/EBP? is genetically or functionally inactivated in many types of myeloid leukemia in which the homeostatic coordination between proliferation and differentiation is lost. Moreover, its ectopic expression in myeloid leukemia lines and in primary blast cells from chronic myelogenous leukemia (CML)-blast crisis patients induces granulocytic differentiation and inhibits proliferation;this suggests that restoring the expression of functional C/EBP? or modulating the activity of C/EBP?-regulated effectors required for proliferation and survival of leukemic stem cells may be a novel anti-leukemia therapy. We found that the transcription repressor Gfi-1, which is important for maintaining the quiescence of hematopoietic stem cells, is required for the proliferation inhibitory effects of C/EBP?. Overexpression of Gfi-1 suppresses proliferation and colony formation of BCR/ABL-transformed cells and its inhibitory effects are reversed by restoring the expression of STAT 5 and Mcl-1, two transcriptionally repressed Gfi-1 targets important for proliferation and survival of normal and leukemic stem cells. These findings support the existence of a C/EBP?-Gfi-1-STAT5/Mcl-1 regulatory pathway that could be exploited therapeutically for the elimination of CML stem cells. Thus, two alternative approaches are proposed here to assess the therapeutic potential of perturbing C/EBP?-regulated pathways in CML stem cells: i) the use of C/EBP? itself delivered as a biologically active protein to primitive CML cells;ii) the genetic and pharmacological targeting of C/EBP? -Gfi-1-regulated genes specifically required for the proliferation/survival of CML stem cells.
When ectopically expressed, the transcription factor C/EBP? inhibits the proliferation of CML-blast crisis cells via Gfi-1 and its targets STAT 5 and Mcl-1, supporting the existence of a C/EBP?-dependent regulatory pathway that could be exploited therapeutically for the elimination of CML stem cells. In this proposal, we will assess the therapeutic potential of perturbing C/EBP?-regulated pathways in CML stem cells upon delivery of C/EBP? itself as a biologically active protein to primitive CML cells and targeting the expression/activity of C/EBP? -Gfi-1-regulated genes specifically required for the proliferation/survival of CML stem cells.
|Minieri, Valentina; De Dominici, Marco; Porazzi, Patrizia et al. (2018) Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia. Cancer Res 78:5793-5807|
|De Dominici, Marco; Porazzi, Patrizia; Soliera, Angela Rachele et al. (2018) Targeting CDK6 and BCL2 Exploits the ""MYB Addiction"" of Ph+ Acute Lymphoblastic Leukemia. Cancer Res 78:1097-1109|
|Mariani, S A; Minieri, V; De Dominici, M et al. (2016) CDKN2A-independent role of BMI1 in promoting growth and survival of Ph+ acute lymphoblastic leukemia. Leukemia 30:1682-90|
|Riva, Beatrice; De Dominici, Marco; Gnemmi, Ilaria et al. (2016) Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of ?-catenin and mTORC1/2. Oncotarget 7:81555-81570|
|Manzotti, Gloria; Parenti, Sandra; Ferrari-Amorotti, Giovanna et al. (2015) Monocyte-macrophage differentiation of acute myeloid leukemia cell lines by small molecules identified through interrogation of the Connectivity Map database. Cell Cycle 14:2578-89|
|Liao, Zhiyong; Gu, Lei; Vergalli, Jenny et al. (2015) Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia. Mol Cancer Ther 14:1777-93|
|Ferrari-Amorotti, Giovanna; Chiodoni, Claudia; Shen, Fei et al. (2014) Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity. Neoplasia 16:1047-58|